Takeda Pharmaceutical Company (TKDA) Stock Statistics & Valuation Metrics

Takeda Pharmaceutical Company has a market cap or net worth of EUR 60.13B. The enterprise value is EUR 85.30B.

Market Cap

EUR 60.13B

Enterprise Value

EUR 85.30B

Takeda Pharmaceutical Company has 3,204,437,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

3,204,437,000

Owned by Insiders

0.12%

Owned by Institutions

0.09%

Takeda Pharmaceutical Company’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is 3.11%.

Return on Equity (ROE)

0.03

Return on Assets (ROA)

0.01

Return on Invested Capital (ROIC)

3.11%

Return on Capital Employed (ROCE)

0.04

Revenue Per Employee

101.59M

Profits Per Employee

4.32M

Employee Count

47,029

Asset Turnover

0.31

Inventory Turnover

1.67

The current PE Ratio of Takeda Pharmaceutical Company is 27.16. Takeda Pharmaceutical Company’s PEG ratio is 0.03.

PE Ratio

27.16

PS Ratio

2.26

PB Ratio

1.40

Price to FCF

18.07

Price to Operating Cash Flow

13.42

PEG Ratio

0.03

In the last 12 months, Takeda Pharmaceutical Company had revenue of 4.78T and earned 203.33B in profits. Earnings per share was 63.91.

Revenue

4.78T

Gross Profit

2.44T

Operating Income

573.04B

Pretax Income

275.88B

Net Income

203.33B

EBITDA

1.38T

Earnings Per Share (EPS)

63.91

In the last 12 months, operating cash flow was 832.59B and capital expenditures -385.11B, giving a free cash flow of 447.47B billion.

Operating Cash Flow

832.59B

Free Cash Flow

447.47B

Free Cash Flow per Share

188.17

Takeda Pharmaceutical Company pays an annual dividend of ―, resulting in a dividend yield of 3.02%

Dividend Per Share

―

Dividend Yield

3.02%

Payout Ratio

N/A

Free Cash Flow Yield

5.53%

Earnings Yield

3.70%

Beta

0.33

52-Week Price Change

52.50%

50-Day Moving Average

16.11

200-Day Moving Average

14.73

Relative Strength Index (RSI)

65.53

Average Volume (3m)

265

Takeda Pharmaceutical Company upcoming earnings date is Jan 28, 2027, TBA (Not Confirmed).

Last Earnings Date

Oct 29, 2026

Next Earnings Date

Jan 28, 2027

Ex-Dividend Date

―

Takeda Pharmaceutical Company as a current ratio of 1.27, with Debt / Equity ratio of 62.80%

Current Ratio

1.27

Quick Ratio

0.70

Debt to Market Cap

0.53

Net Debt to EBITDA

3.13

Interest Coverage Ratio

1.51

In the past 12 months, Takeda Pharmaceutical Company has paid 72.27B in taxes.

Income Tax

72.27B

Effective Tax Rate

0.26

Takeda Pharmaceutical Company EV to EBITDA ratio is 11.20, with an EV/FCF ratio of 25.14.

EV to Sales

3.15

EV to EBITDA

11.20

EV to Free Cash Flow

25.14

EV to Operating Cash Flow

19.08

Takeda Pharmaceutical Company has EUR 454.40B in cash and marketable securities with EUR 4.58T in debt, giving a net cash position of -EUR 4.12T billion.

Cash & Marketable Securities

EUR 454.40B

Total Debt

EUR 4.58T

Net Cash

-EUR 4.12T

Net Cash Per Share

-EUR 1,286.11

Tangible Book Value Per Share

-EUR 470.08

Gross margin is 62.49%, with operating margin of 13.26%, and net profit margin of 8.20%.

Gross Margin

62.49%

Operating Margin

13.26%

Pretax Margin

8.52%

Net Profit Margin

8.20%

EBITDA Margin

28.12%

EBIT Margin

14.80%

The average price target for Takeda Pharmaceutical Company is EUR 38.51, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target

EUR 38.51

Price Target Upside

110.43% Upside

Analyst Consensus

Moderate Buy

Analyst Count

1

Revenue Growth Forecast

-4.28%

EPS Growth Forecast

12.36%

Smart Score

8

AI Score

―